Skip Navigation

DRUG RECORD

 

TALAZOPARIB

OVERVIEW
Talazoparib

 

Introduction

Talazoparib is an orally available small molecule inhibitor of the DNA repair enzyme poly ADP-ribose polymerase (PARP) which is used as an antineoplastic agent in the treatment of selected cases of breast cancer.  Talazoparib is associated with a moderate rate of serum aminotransferase elevations during therapy and is suspected to cause rare instances of clinically apparent acute liver injury.

 

Background

Talazoparib (tal" a zoe' pa rib) is a potent small molecule inhibitor of polyadenosine 5’-diphosphoribose (ADP-ribose) polymerase (PARP), an enzyme involved in repair of single strand breaks in DNA and which is used in the therapy of breast cancer.  In normal cells, DNA repair mechanisms include base excision repair for single strand DNA breaks, for which PARP plays an important role, and homologous recombination for double-strand DNA breaks for which the tumor suppressor proteins BRCA-1 and BRCA-2 are involved.  In patients with cancers associated with BRCA mutations, and particularly those with breast and ovarian cancer, the cancer cells are particularly susceptible to PARP inhibitors which cause accumulation of DNA breaks and resultant cell necrosis.  In several clinical trials, talazoparib has been found improve progression free survival in patients with advanced or metastatic HER-2 negative breast cancer with BRCA mutations.  It is also being evaluated as therapy of other types of solid tumors that harbor germ-line BRCA mutations.  Talazoparib was approved for therapy of breast cancer (HER negative, BRCA positive) in the United States in 2018 and is available in capsules of 0.25 and 1.0 mg under the brand name Talzenna.  The recommended dose is 1 mg orally once daily, continued until progressive disease or intolerable toxicity occurs.  Side effects are common and can include fatigue, nausea, vomiting, diarrhea, anorexia, headache, alopecia, anemia, neutropenia and thrombocytopenia.  Uncommon, but potentially severe side effects include myelodysplastic syndromes, marked myelosuppression and embryo-fetal toxicity.

 

Hepatotoxicity

Elevations in serum aminotransferase levels are common during talazoparib therapy occurring in 33% of patients, but rising above 5 times the upper limit of the normal range in only 1%.  The elevations are generally transient and not associated with symptoms or jaundice.  Furthermore, similar rates of aminotransferase elevations were reported in control, comparator arms.  Talazoparib has had limited clinical use but has not been linked to instances of acute liver injury with symptoms or jaundice.  Because of the limited clinical experience with using talazoparib and other PARP inhibitors, their potential for causing liver injury is not well defined.

Likelihood score: E* (unproved but suspected cause of clinically apparent liver injury).

 

Mechanism of Injury

The possible cause of the liver injury due to talazoparib is not known.  Talazoparib has minimal hepatic metabolism and does not inhibit any of the major cytochrome P450 (CYP) metabolizing enzymes.

 

Outcome and Management

Talazoparib therapy has been associated with transient serum aminotransferase elevations during therapy, but has not been linked to instances of acute liver injury with jaundice or symptoms.  Serum aminotransferase elevations above 5 times the upper limit of normal (if confirmed) should lead to temporary discontinuation, which should be permanent if laboratory values do not improve significantly or resolve within a few weeks or if symptoms or jaundice arise.


Drug Class:  Antineoplastic Agents, Protein Kinase Inhibitors

 

Top of page


 

REPRESENTATIVE TRADE NAMES
Talazoparib – Talzenna®

 

DRUG CLASS
Antineoplastic Agents

 

COMPLETE LABELING

Product labeling at DailyMed, National Library of Medicine, NIH

 

Top of page


DRUG CAS REGISTRY NO. MOLECULAR FORMULA STRUCTURE
Talazoparib 1207456-01-6 C19-H14-F2-N6-O Talazoparib chemical structure

Top of page


 

References updated: 20 January 2019
Abbreviation: PARP, polyadenosine-5’-diphosphoribose polymerase.

  1. Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999.  (Review of hepatotoxicity published in 1999 before the availability of kinase inhibitors).

  2. DeLeve LD. Erlotinib. Cancer chemotherapy. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 556.  (Review of hepatotoxicity of cancer chemotherapeutic agents published in 2013 before the availability of talazoparib and the small molecule PARP inhibitors).

  3. Wellstein A, Giaccone G, Atkins MB, Sausville EA. Pathway-targeted therapies: monoclonal antibodies, protein kinase inhibitors, and various small molecules. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 1203-36.  (Textbook of pharmacology and therapeutics).

  4. https://www.accessdata.fda.gov/scripts/cder/daf/  (FDA Drug Approvals website that has product labels [package inserts], letters of approval and full FDA scientific review of the new drug application for safety and efficacy; mentions that serum ALT elevations were frequent during talazoparib therapy, but rates were lower than with standard therapy [34% vs 39%] and there were no cases of ALT elevations with symptoms or jaundice).

  5. de Bono J, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S, Kaye S, S et al. Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers. Cancer Discov 2017; 7: 620-9. PubMed Citation  (Among 110 patients with various BRCA positive solid tumors treated with different doses of talazoparib, the maximum tolerated dose was 1.0 mg/day and extended therapy was associated with complete responses, particularly in those with ovarian and breast cancer; no mention of ALT elevations or hepatotoxicity).

  6. Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, Mina LA, et al. A phase II study of talazoparib after platinum or cytotoxic nonplatinum regimens in patients with advanced breast cancer and germline BRCA1/2 Mutations (ABRAZO). Clin Cancer Res 2018 Dec 18. [Epub ahead of print] PubMed Citation  (Among 83 women with advanced breast cancer and BRCA mutations treated with talazoparib, the overall objective response rate was 28% and while rates of ALT elevations were not provided, two subjects stopped treatment early because of liver test abnormalities).

  7. Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA Mutation. N Engl J Med 2018; 379: 753-63. PubMed Citation  (Among 431 women with advanced breast cancer with BRCA mutations with talazoparib or single-agent standard therapy, median progression free survival was longer with talazoparib [8.6 vs 5.6 months], while serious adverse event rates were similar [32% vs 29%] and “hepatic toxicity” was less frequent [9% vs 20%]).

  8. Gunjur A. Talazoparib for BRCA-mutated advanced breast cancer. Lancet Oncol 2018; 19: e511. PubMed Citation  (News report on results of trial of talazoparib for breast cancer [Litton 2018] stressing the need to compare talazoparib with standard first-line platinum-based chemotherapy and to better understand mechanisms of resistance to PARP inhibitors).

  9. Hoy SM. Talazoparib: first global approval. Drugs 2018; 78: 1939-46. PubMed Citation  (Review of the mechanism of action, history of development, structure, pharmacology, efficacy and safety of talazoparib; mentions that “hepatic adverse events” were less frequent with talazoparib than standard therapy [9% vs 20%], but one patient died of suspected sinusoidal obstruction syndrome).

Top of page

 

OTHER REFERENCE LINKS
Talazoparib
  1. PubMed logoRecent References on Talazoparib

  2. Clinical Trials logoTrials on Talazoparib

Top of page